Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel in first-line HER2-positive metastatic breast cancer
jRCT2080220775Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Pertuzumab + trastuzumab + docetaxel with Placebo + trastuzumab + docetaxel (2 arms). Primary endpoint: Progression-free survival. Started Jul 2009; status: completed.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080220775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220775.